Frontage Holdings Corp
HKEX:1521

Watchlist Manager
Frontage Holdings Corp Logo
Frontage Holdings Corp
HKEX:1521
Watchlist
Price: 1.08 HKD Market Closed
Market Cap: HK$2.2B

Frontage Holdings Corp
Research & Development

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Frontage Holdings Corp
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
Frontage Holdings Corp
HKEX:1521
Research & Development
-$5m
CAGR 3-Years
-18%
CAGR 5-Years
-25%
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Research & Development
-$1.4B
CAGR 3-Years
2%
CAGR 5-Years
-3%
CAGR 10-Years
-7%
Danaher Corp
NYSE:DHR
Research & Development
-$1.6B
CAGR 3-Years
-2%
CAGR 5-Years
-3%
CAGR 10-Years
-6%
Waters Corp
NYSE:WAT
Research & Development
-$195.7m
CAGR 3-Years
-4%
CAGR 5-Years
-7%
CAGR 10-Years
-5%
Agilent Technologies Inc
NYSE:A
Research & Development
-$454m
CAGR 3-Years
-1%
CAGR 5-Years
2%
CAGR 10-Years
-4%
IQVIA Holdings Inc
NYSE:IQV
Research & Development
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Frontage Holdings Corp
Glance View

Frontage Holdings Corp. engages in the provision of research and analytical and development services throughout the drug discovery and development process. The company is headquartered in Exton, Pennsylvania. The company went IPO on 2019-05-30. Its segments include North America and the People’s Republic of China (PRC). Its North America segment, including laboratory testing, chemistry, manufacturing and control (CMC), preclinical research and chemistry services in the United States of America and Canada. Its PRC segment including laboratory testing, CMC, preclinical research, bioequivalence clinical and chemistry services in the PRC. Its preclinical research includes drug metabolism and pharmacokinetic (DMPK), safety, chemical and toxicology, and laboratory testing, including bioanalytical and biologics, and central laboratory. Its services and solutions include drug candidate evaluation, product development, clinical services and central laboratory and testing services.

Intrinsic Value
1.18 HKD
Undervaluation 9%
Intrinsic Value
Price

See Also

What is Frontage Holdings Corp's Research & Development?
Research & Development
-5m USD

Based on the financial report for Jun 30, 2025, Frontage Holdings Corp's Research & Development amounts to -5m USD.

What is Frontage Holdings Corp's Research & Development growth rate?
Research & Development CAGR 5Y
-25%

Over the last year, the Research & Development growth was 12%. The average annual Research & Development growth rates for Frontage Holdings Corp have been -18% over the past three years , -25% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett